This study is testing a treatment called transcranial direct current stimulation (tDCS) to see if it can help reduce opioid relapse in people with Opioid Use Disorder. tDCS uses a device to deliver a small electrical current to specific areas of the brain. Researchers will compare active tDCS to a sham (inactive) tDCS. The main goal is to see if tDCS can reduce opioid craving after two weeks. You may be able to join if you are 21-60 years old, have current opioid dependence, and recently started buprenorphine or methadone treatment (within the last 90 days). You also need to be receiving opioid treatment services at Butler Hospital or in the community. The study aims to enroll 100 participants.

Study design

This is a randomized clinical trial, meaning participants will be randomly assigned to receive either active tDCS or sham tDCS. The study plans to enroll 100 participants.

What's involved

You would receive five sessions of tDCS or sham tDCS. You will have brain activity (EEG) measurements before, right after the 5 sessions, and again 10 weeks later.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for long-term outcomes, including opioid relapse and craving, for 3 and 6 months during 24 weeks of buprenorphine or methadone maintenance treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.